CLAS Stock Overview
Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Claritas Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.025 |
| 52 Week High | CA$0.27 |
| 52 Week Low | CA$0.025 |
| Beta | 2.6 |
| 1 Month Change | 0% |
| 3 Month Change | -16.67% |
| 1 Year Change | -90.39% |
| 3 Year Change | -95.83% |
| 5 Year Change | -98.68% |
| Change since IPO | -99.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| CLAS | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | -3.6% | -2.1% |
| 1Y | -90.4% | 58.0% | 3.6% |
Return vs Industry: CLAS underperformed the Canadian Pharmaceuticals industry which returned -32.9% over the past year.
Return vs Market: CLAS underperformed the Canadian Market which returned -0.8% over the past year.
Price Volatility
| CLAS volatility | |
|---|---|
| CLAS Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 14.2% |
| Market Average Movement | 9.2% |
| 10% most volatile stocks in CA Market | 18.4% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: CLAS's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CLAS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Bob Farrell | claritaspharma.com |
Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021. The company was founded in 2014 and is headquartered in San Rafael, California.
Claritas Pharmaceuticals, Inc. Fundamentals Summary
| CLAS fundamental statistics | |
|---|---|
| Market cap | CA$944.66k |
| Earnings (TTM) | CA$2.50m |
| Revenue (TTM) | n/a |
0.4x
P/E Ratio0.0x
P/S RatioIs CLAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLAS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | -US$1.80m |
| Earnings | US$1.81m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.048 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 16.4% |
How did CLAS perform over the long term?
See historical performance and comparison